Open AccessJournal Article
Oxidative stress in neurodegeneration: cause or consequence?
TLDR
The evidence for oxidative stress in neurodegeneration is reviewed and how this relates to other cellular events in the emerging roadmap leading to neurodegenesis is reviewed.About:
This article is published in Neurodegeneration.The article was published on 2004-01-01 and is currently open access. It has received 168 citations till now. The article focuses on the topics: Neurodegeneration.read more
Citations
More filters
Journal ArticleDOI
Gender dimorphic formation of Mallory-Denk bodies and the role of xenobiotic metabolism and oxidative stress
TL;DR: Gender dimorphic formation of MDBs and porphyria associate with differences in CYPs, oxidative injury, and selective keratin induction, and these findings may extend to human MDB and other neuropathy- and myopathy-related inclusions.
Single Walled Carbon Nanotubes in High Concentrations is Cytotoxic to the Human neuronal Cell LN18
Journal ArticleDOI
Epigallocatechin-3-Gallate (EGCG): New Therapeutic Perspectives for Neuroprotection, Aging, and Neuroinflammation for the Modern Age
TL;DR: The neuroinflammatory and neuroprotective role of epigallocatechin-3-gallate (EGCG): the medicinal component of green tea, a known nutraceutical that has shown promise in modulating AD progression due to its antioxidant, anti-inflammatory, and anti-aging abilities is highlighted.
Journal ArticleDOI
Hallmarks of neurodegenerative diseases
David M. Wilson,Mark R. Cookson,Ludo Van Den Bosch,Henrik Zetterberg,David M. Holtzman,Ilse Dewachter +5 more
TL;DR: In this article , the authors present evidence for the following eight hallmarks of neurodegenerative diseases: pathological protein aggregation, synaptic and neuronal network dysfunction, aberrant proteostasis, cytoskeletal abnormalities, altered energy homeostasis and DNA and RNA defects.
Journal ArticleDOI
Neuroinflammation in Parkinson’s Disease – Putative Pathomechanisms and Targets for Disease-Modification
TL;DR: The possible contribution of interconnected pathways related to the immune response, focusing on the pathophysiology and neurodegeneration of PD, is discussed and an overview of clinical trials targeting neuroinflammation in PD is provided.
References
More filters
Journal ArticleDOI
Free radicals and antioxidants in normal physiological functions and human disease
TL;DR: Attention is focussed on the ROS/RNS-linked pathogenesis of cancer, cardiovascular disease, atherosclerosis, hypertension, ischemia/reperfusion injury, diabetes mellitus, neurodegenerative diseases, rheumatoid arthritis, and ageing.
Journal ArticleDOI
Nitric Oxide and Peroxynitrite in Health and Disease
TL;DR: Current evidence indicates that most of the cytotoxicity attributed to NO is rather due to peroxynitrite, produced from the diffusion-controlled reaction between NO and another free radical, the superoxide anion, which is presented in detail in this review.
Journal ArticleDOI
Chronic systemic pesticide exposure reproduces features of Parkinson's disease
TL;DR: It is reported that chronic, systemic inhibition of complex I by the lipophilic pesticide, rotenone, causes highly selective nigrostriatal dopaminergic degeneration that is associated behaviorally with hypokinesia and rigidity.
Journal ArticleDOI
Reactive oxygen species (ROS) homeostasis and redox regulation in cellular signaling
TL;DR: This review focuses on the molecular mechanisms through which ROS directly interact with critical signaling molecules to initiate signaling in a broad variety of cellular processes, such as proliferation and survival, ROS homeostasis and antioxidant gene regulation, mitochondrial oxidative stress, apoptosis, and aging.
Journal ArticleDOI
A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease. The Alzheimer's Disease Cooperative Study
Mary Sano,Christopher Ernesto,Ronald G. Thomas,Melville R. Klauber,Kimberly Schafer,Michael Grundman,Peter B. Woodbury,John H. Growdon,Carl W. Cotman,Eric Pfeiffer,Lon S. Schneider,Leon J. Thal +11 more
TL;DR: In patients with moderately severe impairment from Alzheimer's disease, treatment with selegiline or alpha-tocopherol slows the progression of disease.